Authors
Latest:
Management of Steroid-Refractory Immune-Related Adverse EventsThe increasing utilization of these immune checkpoint inhibitors has presented new of immune-related adverse events that have proven to be extremely challenging to manage.
Latest:
HPV and the Immune System in Head and Neck Cancers: Therapeutic ConsiderationsA review of the role of immune therapy in HPV-associated head and neck squamous cell carcinoma, along with the evidence and perspective behind differing therapeutic considerations.
Latest:
Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the BrainBrain metastasis is common in breast cancer and often has a poor prognosis, but there are several ways to manage brain metastasis in breast cancer including focal therapies as well as systemic options for specific populations, including emerging and novel therapies.
Latest:
Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the BrainBrain metastasis is common in breast cancer and often has a poor prognosis, but there are several ways to manage brain metastasis in breast cancer including focal therapies as well as systemic options for specific populations, including emerging and novel therapies.
Latest:
Pediatric Acute Lymphoblastic LeukemiaONCOLOGY discussed therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), with Susan R. Rheingold, MD, Medical Director of the Oncology Outpatient Clinic and attending physician with the Cancer Center at Children’s Hospital of Philadelphia.
Latest:
Monitoring for Thyroid Cancer RecurrenceAlan N. Peiris, MD spoke with ONCOLOGY about guidelines and strategies for treating patients who have had thyroid cancer.
Latest:
Erdafitinib in the Treatment of Metastatic Urothelial CarcinomaFrancisco Castro-Alonso, MD, and colleagues describe the effects of the use of erdafitinib in a patient with metastatic urothelial bladder cancer.
Latest:
What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?
Latest:
What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?
Latest:
Black, Elderly Patients Less Likely to Receive Treatment for Lung CancerAbout a fifth of patients with lung cancer in the United States receive no treatment at all, while approximately 6 in 10 receive the minimal treatments recommended by the National Comprehensive Cancer Network.
Latest:
2019 World Conference Of Lung Cancer Round-UpFive notable abstracts from the 2019 World Conference on Lung Cancer (WCLC).
Latest:
67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant PotentialSTUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.
Latest:
Median Lobe Urethral Embolus After Focal Ablation of Gleason 7 Prostate CancerThis is the case of a man, aged 56 years, who presented with urinary intermittency, frequency, urgency, and dysuria 5 months after undergoing focal laser ablation (FLA) of Gleason 3 + 4 = 7 prostate cancer (PC).
Latest:
67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant PotentialSTUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.
Latest:
Biliary Cancer: Current Multimodality Treatment and Future DirectionsClinicians discuss appropriate evaluation and choice of management strategies for cholangiocarcinoma.
Latest:
Biliary Cancer: Current Multimodality Treatment and Future DirectionsClinicians discuss appropriate evaluation and choice of management strategies for cholangiocarcinoma.
Latest:
Therapy Options for Patients With Hepatocellular CarcinomaTherapy options for patients with hepatocellular carcinoma (HCC), including a newly approved therapy for a subpopulation of patient.
Latest:
Patient Survival Rates in High-Grade Spinal MeningiomaResearchers recently looked at differences in survival time between patients with grade II and grade III spinal meningioma.
Latest:
Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?Metastasis-directed therapy with stereotactic ablative radiotherapy has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer.
Latest:
Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?Metastasis-directed therapy with stereotactic ablative radiotherapy has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer.
Latest:
OncView™ Podcast: Updates in Managing Extensive-Stage Small Cell Lung CancerThis special edition of the “Oncology Peer Review On-The-Go” dives into recent updates and important treatment strategies for extensive-stage SCLC management.
Latest:
Classifying DLBCL Subtypes for Optimal TreatmentJennifer Crombie, MD, discusses classification of diffuse large B-cell lymphoma (DLBCL) into distinct subtypes and treatment decisions based on molecular classifications.
Latest:
Mutations and the Importance of Genetic TestingDr. Allison W. Kurian discusses a new breast cancer study that analyzed the mutations present in breast tumors, and about emerging targeted therapy options.
Latest:
Deep Learning Models Expedite Biomarker Discovery, Detection in Lung CancerInvestigators showcased feasibility of combining pathology findings with deep learning artificial intelligence to speed up biomarker detection and discovery for patients with lung cancer.
Latest:
Real-World Results May Differ From Clinical Trials of CAR T-Cell Therapy Use in DLBCL“When thinking about treatment options for refractory DLBCL you consider: Is it safe to give an older patient CAR T-[cell therapy]?,” said Jennifer Amengual, MD.
Latest:
Sacituzumab Govitecan Combo Yields Early Activity in Metastatic NSCLCData from the phase 2 EVOKE-02 trial support further assessment of sacituzumab govitecan plus pembrolizumab as a frontline treatment for metastatic non–small cell lung cancer.
Latest:
Jason Williams, MD, on Intratumoral Immunotherapy Advances at SITC 2019Jason Williams, MD, discusses the development of intratumoral immunotherapy, as well as trial results from his poster presentation at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Latest:
Joshua Brody, MD, on Cross-Section of Science and Medicine at SITC 2019Joshua Brody, MD, discusses the gratification of the crossover between medicine and science at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Latest:
Experts Identify Steps to Improve Representation of African Americans in Multiple Myeloma Studies“The importance of diverse representation cannot be underscored enough and is critical to ensure that safe and effective products are available to the [United States] patient population,” wrote the study authors, who were led by Nicole Gormley, MD.
